Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daniela Maxim

Nurse Practitioner, Family Troy, MI Nurse Practitioner

NPI 1962892307 CMS profile 11226626

255 Kirts Blvd, Suite 100, Troy, MI 48084

Open in the dashboard

General payments

$111,560

819 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniela Maxim of Troy, MI is reported in the CMS Open Payments database as having received $111,560 across 819 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,565 186
2024 General $29,839 188
2023 General $27,564 163
2022 General $19,803 163
2021 General $20,788 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniela Maxim
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Daniela Maxim were reported at $13,565. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Daniela Maxim Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $20,788 $124 $35–$379 $132
2022 $19,803 $141 $44–$430 $149
2023 $27,564 $154 $49–$476 $160
2024 $29,839 $165 $51–$504 $164
2025 $13,565 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $64,815 159 payments
  2. Genzyme Corporation $19,079 96 payments
  3. Galderma Laboratories, L.P. $13,908 65 payments
  4. Janssen Biotech, Inc. $2,610 117 payments
  5. LEO Pharma Inc. $1,780 40 payments
  6. Sun Pharmaceutical Industries Inc. $1,596 62 payments
  7. UCB, Inc. $1,334 18 payments
  8. AbbVie, Inc. $1,244 66 payments
  9. Novartis Pharmaceuticals Corporation $902 39 payments
  10. E.R. Squibb & Sons, L.L.C. $804 24 payments
  11. Other $3,489 133 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $76,164 61 payments
  2. Food and Beverage $20,095 705 payments
  3. Travel and Lodging $12,433 35 payments
  4. Consulting Fee $1,560 2 payments
  5. Education $1,056 15 payments
  6. Honoraria $252 1 payment
Products named General payments · program years 2021–2025
  1. DUPIXENT Inflammation And Immunology $61,654 135 payments
  2. DUPIXENT Immunology $19,868 117 payments
  3. NEMLUVIO $3,972 14 payments
  4. DUPIXENT Immunology And Inflammation $3,109 22 payments
  5. TREMFYA $2,397 102 payments
  6. Bimzelx $1,243 14 payments
  7. Winlevi $886 26 payments
  8. OPZELURA $706 32 payments
  9. ADBRY $700 32 payments
  10. SOTYKTU $686 21 payments
  11. Other $8,335 389 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,026

Median for Nurse Practitioner: 389

Drug cost

$121,914

Median for Nurse Practitioner: $21,885

Branded share of claims

4.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 27 $98,850
Clobetasol Propionate Generic 119 $4,436
Metronidazole Generic 48 $3,499
Tacrolimus Generic 19 $2,260
Doxycycline Hyclate Generic 66 $1,847
Ketoconazole Generic 104 $1,720
Triamcinolone Acetonide Generic 154 $1,660
Mometasone Furoate Generic 52 $1,090
Azelaic Acid Generic 11 $1,071
Mupirocin Generic 143 $945

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$246,387

Of which drugs: $160,092

Medicare patients

379

Average age 75

Services billed

4,077

234 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 43%
Ischemic heart disease 29%
Diabetes 22%
Chronic kidney disease 20%
Atrial fibrillation 16%
Osteoporosis 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$17,065 27 —
SOTYKTU
$458 — —
TREMFYA
$403 — —
OPZELURA
$266 — —
Otezla
$188 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

819 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record